PRGN-3007

N/A

Report date: 2023/05/05 17:41:28

Base Information

Drug NamePRGN-3007

Drug Alias NamePRGN-3007

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionWnt signalling pathway modulatorsInactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists

TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1

Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsTriple Negative Breast Neoplasms +[7]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesPrecigen Inc

China Registration ClassN/A

Develop Information

Active CompaniesH Lee Moffitt Cancer Center & Research Institute Precigen Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursHematologic NeoplasmsTriple Negative Breast Neoplasms +[7]

Inactive IndicationsN/A

Other Information

ATC CodeN/A